Viyash Scientific Ltd.
Fundamentals
- Market cap
- ₹11,756 cr
- P/E
- 66.32×
- ROE
- 3.11%
- Debt / equity
- 0.63
- 52-week range
- 166.20 — 278.80
Company snapshot
Viyash Scientific Ltd.
Pharmaceuticals
₹11,756 cr
P/E 154.95×
Latest quarter · Mar 2026
Sales₹920 cr
Net profit₹66 cr
Op. margin+20.0%
EPS₹1.19
Strength & growth
Debt / equity0.63×
Current ratio1.68×
Sales CAGR+15.8%
EPS CAGR−15.6%
The timeline — 4 notes on Viyash Scientific Ltd.
June 2026
- 08 Jun 26 · 12:46 PM IST Brief Brief · M&A · Mid cap
Viyash's Italian pet-care bid jumps 28% to ₹188 cr
The final price for BioForLife is ₹41 crore above the figure Viyash disclosed earlier this year. The deal remains small against the company's own scale.
- 08 Jun 26 · 12:41 PM IST Brief Brief · M&A · Mid cap
Viyash buys Italian vet distributor for €17M
The €16.975M cash deal adds a direct sales platform in Italy's companion animal market. It's a strategic, not a financial, move for the mid-cap.
May 2026
- 22 May 26 · 10:36 AM IST Brief Brief · Earnings · Mid cap
Viyash Scientific posts record quarter, sets ₹800 cr EBITDA run-rate for FY27
Q4 revenue hit ₹920 crore and EBITDA jumped 64% to ₹200 crore. Management now sees the full-year EBITDA run-rate approaching ₹800 crore.
- 21 May 26 · 8:15 AM IST Brief Brief · Concalls · Mid cap
Viyash Scientific targets ₹1,000 cr EBITDA in 2-3 years, pivots to companion animals
Management's May concall reaffirms synergy-led margin expansion and sets an FY27 EBITDA run rate of ~₹800 crore.